SCHEMBL20904164

SCHEMBL20904164

CC(C)(C)OC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)OC(C)(C)C)(COCCC(=O)NCCCNC(=O)OC(C)(C)C)NC(=O)CCCCCCCCCCC(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.46
TPSAB1 Q15661 1/20 0.42
TPSD1 Q9BZJ3 1/20 0.42
TPSG1 Q9NRR2 1/20 0.42
IDO1 P14902 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
MAPT P10636 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25346919 0.98 CYP3A4 (0.48) CYP3A4TPSAB1TPSD1TPSG1IDO1
SCHEMBL18705411 0.97 CYP3A4 (0.43) CYP3A4TPSAB1TPSD1TPSG1IDO1
SCHEMBL22946820 0.94 HPGD (0.41) CYP3A4IDO1HDAC3HDAC4HDAC1
SCHEMBL22021517 0.93 EPHX2 (0.41) CYP3A4HDAC3HDAC4HDAC1HDAC7
SCHEMBL10177563 0.89 HTT (0.47) CYP3A4IDO1HDAC3HDAC4HDAC1
SCHEMBL29959208 0.88 HTT (0.49) CYP3A4IDO1HDAC3HDAC4HDAC1
SCHEMBL18879474 0.88 MAPT (0.48) CYP3A4IDO1HDAC3HDAC4HDAC1
SCHEMBL25752594 0.88 HPGD (0.48) CYP3A4HDAC3HDAC4HDAC1HDAC7
SCHEMBL27250873 0.87 HDAC8 (0.41) HDAC8MAPTL3MBTL1SYKEPHX2
SCHEMBL17599919 0.87 CYP3A4 (0.59) CYP3A4TPSAB1TPSD1TPSG1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240175018-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-05-30 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230220384-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-07-13 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
EP-4153604-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2023-03-29 EP disclosed
EP-4153747-A2 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO Wave Life Sciences Ltd. (SG) 2023-03-29 EP disclosed
EP-4022059-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF Wave Life Sciences Ltd. (SG) 2022-07-06 EP disclosed
US-20210228615-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2021-07-29 US disclosed
US-20210198305-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF PFIZER INC. 2021-07-01 US disclosed
WO-2021071858-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2021-04-15 WO disclosed
US-20200190515-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-06-18 US disclosed
US-20200190515-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-06-18 US disclosed
US-20200157545-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-05-21 US disclosed
US-20200157545-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-05-21 US disclosed
WO-2019075357-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240175018-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF RNASE1, RNASEH1, RNASEL CYP3A4 4763/4885TPSAB1 3477/4885TPSD1 3494/4885
US-20200190515-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF RNASE1, RNASEH1, RNASEL CYP3A4 4763/4885TPSAB1 3477/4885TPSD1 3494/4885
US-20210228615-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF SMN1; SMN2, RBM17, RBM22 CYP3A4 4875/4885TPSAB1 4858/4885TPSD1 4824/4885
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 CYP3A4 4595/4885TPSAB1 4634/4885TPSD1 4525/4885
US-20200157545-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF RNASE1, RNASEH1, RNASEL CYP3A4 4846/4885TPSAB1 3679/4885TPSD1 4017/4885
US-20210198305-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF RNASE1, RNASEH1, NSUN3 CYP3A4 4737/4885TPSAB1 4206/4885TPSD1 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.